ABOUT THE EVENT

Delivered digitally to help manage travel and physical distancing restrictions, the organising committee for 6th BDP China is delighted to present an innovative and creative format for the event.

Repurposed to address the emerging and likely permanent shifts in the Chinese biopharma industry, key leaders in the region will convene online to discuss investment climate beyond 2020, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.

With live-streaming sessions, smart networking windows and elevated exhibition platforms at our virtual BDP China, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.

WHO WILL YOU MEET?

BY INDUSTRY:
- China/MNC Pharma & Biotech .................................................. 50%
- CDMOs/CROs/CMOs ................................................................. 25%
- Tech Solution Providers ............................................................... 10%
- Regulators, Healthcare Agencies & Associations ...................... 5%
- Scientific Research & Universities ........................................... 5%
- Others .......................................................................................... 5%

BY GEOGRAPHY:
- China ........................................................................................... 50%
- Japan, Korea, HK, Taiwan .......................................................... 15%
- Southeast Asia ............................................................................... 10%
- USA ............................................................................................... 10%
- Europe ........................................................................................... 10%
- Other Region .................................................................................. 5%

OUR MARKETING AND DIGITAL MEDIA OUTREACH

83000+ Unique Pageviews
76 Countries
34000+ LinkedIn Impressions
# AGENDA AT-A-GLANCE

## Day 1 of Main Conference  |  Tuesday, 3 November 2020

**KEYNOTE ADDRESS**  
China's Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization

**KEYNOTE ADDRESS**  
China's Biological Facilities for the Future – WuXi’s Story on Technology & Innovation

### 10th ANNUAL

**BIO MANUFACTURING**

- Biomanufacturing 2030 – the hottest shifts in manufacturing in China
- Trends in Pharma 4.0 standards and China’s new drug delivery strategy
- Industry case studies for commercial manufacturing

### 9th ANNUAL

**CELL LINE DEVELOPMENT & ENGINEERING ASIA**

- The state-of-play for cell line development
- Applications for furthering biopharma R&D strategy
- Novel CLD platform technologies and tools
- Industry case studies for high-throughput screening and performance

### 2nd ANNUAL

**CELL & GENE THERAPY MANUFACTURING**

- Maneuvering the Chinese Market for Cell and Gene Therapies
- Addressing the next wave of innovations in cell therapies

## Day 2 of Main Conference  |  Wednesday, 4 November 2020

**Manufacturers’ Panel:**

New Therapies, New Tech & New Investments

### 10th ANNUAL

**BIO MANUFACTURING**

- Smarty biomanufacturing and process optimization
- Manufacturing technology showcases – Improving cost and efficiency
- Innovative bioprocess development
- Sustainable manufacturing and scalability

### 9th ANNUAL

**CELL LINE DEVELOPMENT & ENGINEERING ASIA**

- Advancements in cell engineering techniques for complex proteins
- CRISPR and genomics in focus
- Data-driven, accelerated, and next-generation CLD
- Industry Panel: Perspectives on utilising platform technologies for CLD

### 2nd ANNUAL

**CELL & GENE THERAPY MANUFACTURING**

- Managing cost and accelerating manufacturing process
- Latest CAR T-cell technology developments
- Facilities design and construction cell therapies

## Day 3 of Main Conference  |  Thursday, 5 November 2020

**KEYNOTE ADDRESS**  
China's Biopharma Capital Markets – Future Funds & Innovative Financing

**Venture Capitals Roundtable: Show Me the Drug**

### 10th ANNUAL

**BIO MANUFACTURING**

- DAL’s New GAMP and Licensing Law – Implementation and oversight
- QbD and Quality Matrix for meeting regulatory requirements
- Biomanufacturing process validation and quality risk management
- Best practices and strategies in biopharma supply chain integration

### 9th ANNUAL

**CELL LINE DEVELOPMENT & ENGINEERING ASIA**

- Optimising workflows and bioprocesses
- Exploring the synergies between engineered host cells and process development for commercial success
- Industry Panel: what’s next in the future of CLD&E

### 2nd ANNUAL

**CELL & GENE THERAPY MANUFACTURING**

- Investment and commercialisation landscape
- Case studies on clinical trial landscapes and efficacy evidence
CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks

JOINT OPENING PLENARY
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing

13.10 KEYNOTE ADDRESS
China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization
Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13.40 KEYNOTE ADDRESS
China’s Biological Facilities for the Future – WuXi’s Story on Technology and Innovation
Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

16.00 Online Networking & Stretch Break

THE STATE-OF-PLAY FOR CLD

14.10 Online Networking & Stretch Break

9th Annual Cell Line Development & Engineering Asia Conferences

14.20 Chairperson’s Opening Remarks

15.00 Enhancing Complex Protein Expression with Highly Efficient Gene Integration Technology
Senior Representative from Lonza

NOVEL ADVANCES IN CLD TECHNIQUES & TECHNOLOGY

15.30 Next-Generation Cell Line Development with Accelerated Timeline and High-Productivity
Zheng Zhang, Director II, Cell Line Development, WuXi Biologics, China

15.40 Developing a New CLD Process from Ground-Up
Mark Stockdale, Amalgamator of Business and Biology, Solentin, U.K.

16.00 Online Networking & Stretch Break

DAY 2, WEDNESDAY 4 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks

JOINT OPENING PLENARY
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing

13.10 Manufacturers’ Panel:
New Therapies, New Tech and New Investments
Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China (tentatively confirming)
William Cao, Founder, Chairman & CEO, Gracell Biotechnologies Group, China

13.20 Chairperson’s Opening Remarks

14.00 Online Networking & Stretch Break

9th Annual Cell Line Development & Engineering Asia Conferences

14.20 Chairperson’s Opening Remarks

ENGINEERING HOST CELL LINES, GENOMICS & CRISPR IN FOCUS

14.30 Advances in Glycosylation and Expression Vectors for Recombinant Proteins
Dr. Song Zhigang, Principal Scientist, Bioprocessing Technology Institute, A*STAR, Singapore

OPTIMISING WORKFLOWS AND BIOPROCESSSES

14.50 Integrated Cell Line Development Strategy in Whole CMC Picture
Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China

15.00 Enabling New Frontiers in Recombinant Protein Therapeutic Development: A Novel and Modular CHO Expression Platform
Dr. Igor Fisch, Chief Executive Officer, Selecsia, Switzerland

15.30 CRISPR in Cell Line Development:
Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

16.00 Online Networking & Stretch Break

16.20 Next-Generation Cell Line Engineering for Biopharmaceutical Production
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany

17.00 Accelerating CLD for Commercial Success
Dr. Pan Zhiwei, Senior Director, Process Development, Junshi Pharma, China

17.30 Using CHO to Develop Biosimilars from Non-CHO Host Cell Line
Eric Chang, Head, Cell Line Development, JHL Biotech, China

18.00 End of Conference Day 1

DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks

JOINT OPENING PLENARY
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing

13.10 KEYNOTE ADDRESS
China’s Biopharma Capital Markets – Future Funds and Innovation Financing
Fu Wei, Chief Executive Officer, CBC Group, China

13.40 Venture Capitals Roundtable:
Show Me the Drug
Panelists:
Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Biobventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China

14.20 Online Networking & Stretch Break

15.10 Panel Discussion: What’s Next in the Future of CLD&E
Moderator:
Dr. Song Zhigang, Principal Scientist, Bioprocessing Technology Institute, Singapore

Panelists:
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany

15.50 Applications for Glycan Analysis Workflows and Bioanalytical Proteins
Senior Representative, from ProZyme

16.20 Online Networking & Stretch Break

16.40 A Fully Integrated Platform Approach for Highly-Quality CLD
Senior Representative, from Shanghai Henlius Biotech, China

17.00 Panel Discussion: What’s Next in the Future of CLD&E
Moderator:
Dr. Song Zhigang, Principal Scientist, Bioprocessing Technology Institute, Singapore

Panelists:
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany

17.55 End of Conference
CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020

13.00 Opening Address: China’s Big Leap towards BioPharma 2030 — Innovation, Industrialization, Internationalization
Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PHIRDA), China

13.30 Keynote Address: China’s Biologics Facilities for the Future — WuXi’s Story on Technology and Innovation
Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

14.00 Online Networking & Stretch Break

14.20 Trends in Pharma 4.0 Standards and China’s New Drug Delivery Strategy
Dr. Liu Xun, President, Biomedicine Development and Business Division, Jiangsu Hengrui Medicine, China

14.50 Debottlenecking and Process Optimisation in China Biopharma Landscape
Dr. Simon Hsu, Senior Vice President, Technical Operations, Henlius, China

15.20 The New Age of Smart Continuous Manufacturing as Market Moves to Commercial
Dr. Li Jing Rong, Senior Vice President, Product Development and Manufacturing, CSI Pharmaceuticals, China

15.50 Online Networking & Stretch Break

16.00 Keynote Address: China’s Biopharma Capital Markets — Future Funds and Innovative Financing
Fu Wei, Chief Executive Officer, CBC Group, China

16.30 Venture Capitalists’ Roundtable: Show Me the Drug
Moderator: Fu Wei, Chief Executive Officer, CBC Group, China
Panelists:
- Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
- Judith Li, Partner, Lilly Asia Ventures, China
- Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
- Lynn Yang, Managing Director, Sequoia Capital, China
- Dr. John Zhu, Partner, 6 Dimensions Capital, China

17.00 End of Conference Day 1

DAY 2, WEDNESDAY 4 NOVEMBER 2020


13.30 Keynote Address: China’s Biological Facilities for The Future — Growth, Innovation and Investments
Larry Zhang, Chief Executive Officer, CASI Pharmaceuticals, China

13.40 Manufacturing Technology Showcases — Improving Cost and Efficiency
Frank Ye, Senior Vice President, Technical Operations, Transcenta, China

14.00 Online Networking & Stretch Break

14.20 Manufacturing Technology — From Tech Transfer to Risk Analysis and Migration Strategy
Dr. John Zhang, Vice President, Manufacturing Technology and Process Development, Beigene, China

14.50 Manufacturing Technology — From Tech Transfer to Risk Analysis and Migration Strategy
Dr. John Zhang, Vice President, Manufacturing Technology and Process Development, Beigene, China

15.20 Tech Transfer Development for mAb Manufacturing Productivity Optimization
Dr. Zack Zheng, Vice President, Process Development, JHL Biotech, China

15.50 Online Networking & Stretch Break

16.10 Glycosylation of Monoclonal Antibody and the Manipulation
Liu Dong Lian, Vice President, Manufacturing, TOT Biopharm, China

16.40 Vaccine Manufacturing Innovation
Dr. David Shao, President, Chief Executive Officer, Yisheng Biopharma, China

17.10 Case Study: Bio-Works’ 3rd Gen Agarose Resins to Purifying Antibody-based Therapies Using A Different 3-step Column Chromatography Approach
Dr. Bjorn Hammarberg, Business Development Asia, Bio-Works, Sweden

17.40 End of Conference Day 2

DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Keynote Address: China’s Biopharma Quality Assurance Best Practices and PAT Insights
Dr. Yi Jizu, Senior Vice President, CMC and Quality Operations, YZY Biopharma, China

13.30 Biomanufacturing Process Validation and Quality Risk Management
Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

13.40 Integrated CMC Platforms to Develop Robust Downstream Process for Clinical Manufacturing
Dr. Zhang Zhe Ru, President, Head of CMC and Manufacturing, I-MAB Biopharma, China

14.00 Online Networking & Stretch Break

14.30 Ensuring Uninterrupted Supply of Biological Drugs
Yin Nan Po, Director, Asia Supply Chain, Amgen, China

Dr. John Zeng, Executive Vice President, Product Development, and Commercialization, Shanghai Zerun Biotechnology, China

15.10 Impact of NMPA Reform on CMC Strategy at IND Stage
Dr. Ma Yuan Hui, Executive Director, Preclinical Science, Shanghai HailiHe Pharmaceutical, China

15.40 GMP IMPLEMENTATION — THE MADE IN CHINA 2025 PLAN

16.10 Online Networking & Stretch Break

16.30 Biomanufacturing Process Validation and Quality Risk Management
Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

Dr. John Zeng, Executive Vice President, Product Development, and Commercialization, Shanghai Zerun Biotechnology, China

17.10 Case Study: Bio-Works’ 3rd Gen Agarose Resins to Purifying Antibody-based Therapies Using A Different 3-step Column Chromatography Approach
Dr. Bjorn Hammarberg, Business Development Asia, Bio-Works, Sweden

17.40 End of Conference Day 3

18.00 Conference Close
SPONSORS AND EXHIBITORS

GOLD SPONSOR:
Lonza
Pharma & Biotech

BRONZE SPONSORS:

SELEXIS
Solentim

ASSOCIATE SPONSORS:

ILC DOVER
Novo Nordisk Pharmatech A/S

MEDIA PARTNERS:

Unrivalled Opportunity to Profile your Company

Position your company in the networking heart of this event and create great connection with your attendees.

Thought leadership
Offer keynotes and educational sessions to your audience through live webinars or pre-recorded video broadcast with automated reminders, Q & A sessions and polls to keep your attendees engaged.

Informa Data+
Unique option for increased lead generation through retargeting of our global proprietary database in social media.

Powerful Digital Matchmaking
Build valuable relationships with our intelligent matchmaking tool, live chat and integrated 1:1 video calls.

Virtual Booths
Online spaces with your brand identity, showcase your product demos, live chat with audiences. Manage your own logo, description video, collateral, staff profiles and more.

Focused Metrics
Measurable exposure and trackable meetings generate great ROI. Booth views, meeting requests, engagement rates – you’ll have all the data you need.

Accelerated Brand Exposure
Gain prominence with focused digital theatres in the lead up, main conference days, and up to 3 months after the event with our on-demand content modules.

For more information on digital sponsorship opportunities, please contact: Yvonne Leong, +65 9852 3283, Yvonne.Leong@informa.com

www.biopharmaproduction.com
### International Companies – Outside China
*International Companies with Global HQ Located Outside China*

<table>
<thead>
<tr>
<th></th>
<th>Early Bird Rate</th>
<th>Normal Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Individual Rate</strong></td>
<td>USD 595</td>
<td>USD 695</td>
</tr>
<tr>
<td><strong>Group Rates (Price per Delegate)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 or More</td>
<td>USD 495</td>
<td>USD 595</td>
</tr>
<tr>
<td>10 or More</td>
<td>USD 395</td>
<td>USD 495</td>
</tr>
</tbody>
</table>

### Local China Companies

<table>
<thead>
<tr>
<th></th>
<th>Early Bird Rate</th>
<th>Normal Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Individual Rate</strong></td>
<td>USD 895</td>
<td>USD 995</td>
</tr>
<tr>
<td><strong>Group Rates (Price per Delegate)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 or More</td>
<td>USD 795</td>
<td>USD 895</td>
</tr>
<tr>
<td>10 or More</td>
<td>USD 695</td>
<td>USD 795</td>
</tr>
</tbody>
</table>

#### 3 EASY WAYS TO REGISTER

Contact Miki Kong
+65 6508 2477

Registration Enquiry Email
info.sg@informa.com

Website
www.biopharmaproduction.com

---

*Organisers reserved rights to accept/reject complimentary pass applications submitted, also to request specific job functions as described below. This is to ensure you gain maximum benefit from conference content and networking activities.*

**VIP ACCESS FOR PHARMA MANUFACTURERS**

VIP ACCESS FOR PHARMA MANUFACTURERS

**CHINA PHARMACEUTICAL & BIOTECH COMPANIES ATTEND FOR FREE**
*(FOR SPECIFIC JOB TITLES ONLY)*

---

Delegates who have successfully registered for the event will receive their Online Networking System (ONS) details to connect and network with other attendees nearer to the event date!